ํSBHMY โข OTCMKTS
add
์ค๊ตญ์๋ฌผ์ ์ฝ
์ ์ผ ์ข
๊ฐ
$9.05
52์ฃผ ๋ณ๋ํญ
$6.69 - $9.65
์๊ฐ์ด์ก
612.39์ต HKD
ํ๊ท ๊ฑฐ๋๋
50.00
๋ด์ค
์ฌ๋ฌด
์์ต๊ณ์ฐ์
์์ต
์์ด์ต
(CNY) | 2024๋ 6์info | ์ ๋ ๋๋น ๋ณ๋ |
---|---|---|
์์ต | 79.37์ต | 11.14% |
์ด์๋น | 47.80์ต | 10.58% |
์์ด์ต | 15.09์ต | 139.69% |
์์ด์ต๋ฅ | 19.01 | 115.78% |
์ฃผ๋น ์์ต | โ | โ |
EBITDA | 19.75์ต | 8.88% |
์ ํจ ์ธ์จ | 16.99% | โ |
๋์ฐจ๋์กฐํ
์ด์์ฐ
์ด๋ถ์ฑ
(CNY) | 2024๋ 6์info | ์ ๋ ๋๋น ๋ณ๋ |
---|---|---|
ํ๊ธ ๋ฐ ๋จ๊ธฐ ํฌ์ | 131.79์ต | -15.93% |
์ด์์ฐ | 667.04์ต | 1.62% |
์ด๋ถ์ฑ | 245.82์ต | -15.76% |
์ด์๊ธฐ์๋ณธ | 421.22์ต | โ |
๋ฐํ ์ฃผ์ | 182.05์ต | โ |
์ฃผ๊ฐ์์์ฐ๋น์จ | 5.03 | โ |
์ด์์ฐ์ด์ต๋ฅ | 6.50% | โ |
์๋ณธ์ด์ต๋ฅ | 8.37% | โ |
ํ๊ธ ํ๋ฆ
์ํ๊ธํ๋ฆ
(CNY) | 2024๋ 6์info | ์ ๋ ๋๋น ๋ณ๋ |
---|---|---|
์์ด์ต | 15.09์ต | 139.69% |
์์
ํ๊ธ ํ๋ฆ | 15.39์ต | 15.25% |
ํฌ์ ํ๊ธ ํ๋ฆ | -10.20์ต | 49.91% |
์๊ธ ์กฐ๋ฌ ํ๊ธ ํ๋ฆ | -20.50์ต | -1.42% |
์ํ๊ธํ๋ฆ | -15.18์ต | 43.37% |
์์ฌ ํ๊ธ ํ๋ฆ | 10.88์ต | 36.59% |
์ ๋ณด
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a civilian-run enterprise principally engaged in the medicine products business in Mainland China.
Being a member of Charoen Pokphand Group and headquartered in Hong Kong and Beijing, Sino Biopharm is engaged in researching, developing, producing, and selling biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis through its subsidiaries.
Sino Biopharm is also involved in other minor businesses through its subsidiaries, such as properties, health food, optical glass, optical and auditory products. Wikipedia
CEO
์ค๋ฆฝ
2000
์น์ฌ์ดํธ
์ง์ ์
24,437